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Abstract
Background: Home blood pressure monitoring has many benefits, even more so, in populations prone to high blood pressure,
such as persons with diabetes.
Objective: The purpose of this research was to validate the QardioArm mobile device in a sample of individuals with
noninsulin-dependent type 2 diabetes in accordance with the guidelines of the second International Protocol of the European
Society of Hypertension.
Methods: The sample consisted of 33 patients with type 2 diabetes. To evaluate the validity of QardioArm by comparing its
data with that obtained with a digital sphygmomanometer (Omron M3 Intellisense), two nurses collected diastolic blood pressure,
systolic blood pressure, and heart rate with both devices.
Results: The analysis indicated that the test device QardioArm met all the validation requirements using a sample population
with type 2 diabetes.
Conclusions: This paper reports the first validation of QardioArm in a population of individuals with noninsulin-dependent
type 2 diabetes. QardioArm for home monitoring of blood pressure and heart rate met the requirements of the second International
Protocol of the European Society of Hypertension.
(J Med Internet Res 2020;22(7):e19781) doi: 10.2196/19781
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Introduction
Ultimately, devices that automatically measure blood pressure
have gradually evolved to replace the standard mercury
sphygmomanometer, as the risk of mercury toxicity outweighed
any potential benefits of its use. Today there are a wide variety
of devices capable of measuring blood pressure both in and
outside of clinical environments [1-7].
Among the advantages of home blood pressure monitoring are
that it helps to detect white coat and masked hypertension; it is
highly available at a low price; blood pressure measurements
at home are taken in a more natural, relaxed, and domestic
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environment than when taken in the doctor’s office; patient
convenience in blood pressure measurement ensures more
commitment; repeated measurements can be easily taken, and
it can be used over longer periods to assess the daily variability
of blood pressure [8].
But logically, it is a necessary requirement that these devices
have been validated by standardized protocols, such as the
European Society of Hypertension-International Protocol 2
(ESH-IP2) [9], the British Hypertension Society protocol [10],
or the protocol of the Association for the Advancement of
Medical Instrumentation [11].
If this validation is essential in the general population, it is even
more important in at-risk populations, such as patients with
diabetes, where reliability and accurate blood pressure
measurement are essential to avoid the disease’s progression.
Type 2 diabetes is a prevalent disease and represents a very
serious social health problem; it has been seen to occur to a
greater extent in older adults [12,13]. The main complication
of type 2 diabetes is atherosclerotic disease [14,15].
This atherosclerotic disease is the main cause of morbidity and
mortality in people with diabetes, and the one that contributes
the most to the direct and indirect costs of diabetes [16,17]. In
addition, atherosclerosis reduces arterial elasticity, and therefore,
causes arterial stiffness. This arterial wall stiffening produces
a high risk of mortality [14-18]. Furthermore, the occurrence
of stiffened arteries increases with diabetes [19] and
hypertension; therefore, it is common that patients with diabetes
are also hypertensive [18,20,21]. In fact, it is estimated that
more than two-thirds of patients with type 2 diabetes are also
hypertensive [22]. It has also been shown that arterial stiffness
is more critical in individuals with both hypertension and type
2 diabetes than in those without hypertension [23,24]. This is
a major health problem.
For all these reasons, correctly and validly measuring blood
pressure in a person with diabetes is crucial. On one hand, blood
pressure control has been shown to decrease the risk of
diabetes-related complications such as microvascular and
microvascular pathology [16,22-25]. On the other hand, the
increase in arterial stiffness can affect the accuracy of automatic
blood pressure measurements that are essential for diagnosis
and administration [26,27]. And, more importantly, measuring
blood pressure accurately facilitates the establishment of a
threshold above which antihypertensive treatment may be
recommended, especially in patients with type 2 diabetes who
are very likely to develop complications such as peripheral
arterial disease, stroke, heart attack, sudden death from heart
failure, or renal pathologies, if not treated [28,29].
In that regard, it has been proven that blood pressure control
and the prevention of morbidity and related mortality could be
improved in persons with diabetes [3,8,16]. However,
knowledge, treatment, and control of hypertension are
persistently low worldwide [30,31].
One of the great challenges is to avoid therapeutic inertia, as
this would result in an unacceptable burden in terms of human
lives, sequelae, and socioeconomic costs [16,32].
Therefore, we consider it highly relevant to evaluate the validity
of automatic blood pressure measurements in persons with
diabetes because of the high prevalence of hypertension in this
specific population and its significant morbidity and mortality
rate.
The main goal of this study was to test the validity of the
measurements of the QardioArm blood pressure monitoring
device in individuals with noninsulin-dependent type 2 diabetes
persons, in accordance with ESH-IP2 [9]. We hypothesized that
the QardioArm for home blood pressure monitoring
measurements of blood pressure and heart rate in individuals
with noninsulin-dependent type 2 diabetes would be equivalent




We performed an observational concordance study to validate
the QardioArm device for measurement of heart rate, diastolic
blood pressure, and systolic blood pressure, in individuals with
noninsulin-dependent type 2 diabetes according to ESH-IP2 [9]
and STROBE (Strengthening the Reporting of Observational
Studies in Epidemiology) criteria [33]. The study was conducted
between September 2019 to January 2020.
Ethics
This research study received ethical approval (number
173/2019). This study respected the Helsinki Declaration [34].
All participants signed an informed consent form prior to being
included in the study.
Devices
Omron M3 Intellisense
The Omron M3 Intellisense (Omron Healthcare Co Ltd) was
used as the gold standard instead of a mercury
sphygmomanometer, in this study, because it has been validated
in the general population according to ESH-IP2 [35].
The Omron M3 Intellisense device records heart rate in the
range of 40 to 180 bpm and brachial blood pressure in the range
of 0 to 299 mmHg using the oscillometric method; systolic
blood pressure, diastolic blood pressure, and heart rate are shown
on screen. The inflation system does not require pressure
presetting or reinflation because of its technology, and deflation
is automatically released by a pressure valve. It weighs
approximately 340 g without batteries. The standard cuff fits
arm circumferences ranging from 22 to 32 cm; it is also available
in a large cuff to fit arm circumferences from 32 to 42 cm.
QardioArm
The QardioArm (Atten Electronic Co) is an automatic home
blood pressure measurement monitoring device. QardioArm is
a blood pressure measurement system intended to assess heart
rate, diastolic blood pressure, and systolic blood pressure in an
adult population, for pulse rates in the range of 40 to 200 bpm
and blood pressure in the range of 40 to 250 mmHg.
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This device utilizes an inflatable cuff that is wrapped around
the upper arm, with circumferences ranging from 22 to 37 cm.
The weight of unit is 310 g with batteries and its dimensions,
when closed, are 140 mm×68 mm×38 mm. There is a freely
downloadable app on the company’s website, Google Play, or
the Apple App Store. A smart device with Android 4.4 (KitKat)
or later, or Bluetooth 4.0 and iOS 7.0 or later, is required, being
compatible with iPhone, iPod, iPad, Apple Watch, tablets, and
smartphones. QardioArm also provides graphics to facilitate
visual data interpretation on screen. This app may be configured
by warnings and reminders, also measurements and progress
may be shared in real time with clinicians and other users.
Patients and Recruitment
All patients were recruited from Fresenius Medical facilities in
Plasencia-Extremadura, Spain. The inclusion criteria were age
greater than 25 years, gender (at least 10 men and 10 women),
and recruitment blood pressure requirements according to the
guidelines [9]: 33 participants diagnosed with
noninsulin-dependent type 2 diabetes were included.
The exclusion criteria were having an arrhythmia or using
insulin as treatment at the time of the study.
Study Protocol
Two nurses with experience in blood pressure measurement
performed all assessments. The assessment room was a
comfortable temperature without noise, distractions, or any
factors that could have influenced the measurements [9].
Birth date, gender, weight, and height of each participant were
recorded, and the arm circumference was measured in order to
ensure an adequate cuff size. Body mass index was calculated
using the Quetelet index.
The same assessment room was used for all participants. Each
participant was seated in the assessment room, and the
measurements were assessed after a period of 10 to 15 minutes
of rest. Measurements by both units were taken on the left arm
supported at the heart level, and a total of 9 consecutive
measurements (systolic blood pressure, diastolic blood pressure
and heart rate) were carried out alternating the Omron M3
Intellisense and the QardioArm in the following order: blood
pressure A—entry blood pressure using the Omron M3 as
standard device; blood pressure B—entry blood pressure using
the Omron M3 as test device; blood pressure 1 by Omron M3;
blood pressure 2 by QardioArm; blood pressure 3 by Omron
M3; blood pressure 4 by QardioArm; blood pressure 5 by Omron
M3; blood pressure 6 by QardioArm; and blood pressure 7 by
Omron M3.
During measurement, the patient remained quiet and calm,
sitting placing the back straight maintaining the feet over the
floor in parallel position without crossing their legs as well as
resting the arm over a flat surface, with the hand palm upwards
and the elbow in a slightly flexed position in order to place his
fist at the height of its heart. The interval between one
measurement and the next was 30 or 60 seconds [9].
Data Analysis
Results are described as mean and standard deviation with range.
Sociodemographic variables were examined using the
Kolmogorov–Smirnov test to assess normality, and data were
considered normally distribution if P>.05. Two-tailed
independent t tests or Mann–Whitney U tests were used for
parametric or nonparametric variables, respectively.
Device accuracy, following the ESH-IP2 [9], is based on a
comparison between the device and reference measurements.
Part 1 of the protocol refers to the number of differences within
the required ranges for individual measurements (99
measurements), and part 2 of the protocol refers to the number
of differences within the required ranges for each individual
(n=33).
For each patient, systolic blood pressure measurements obtained
from the QardioArm device (blood pressure measurements 2,
4, and 6) were compared with the systolic blood pressure
measurements from the Omron device (blood pressure
measurements 1, 3, and 5, respectively, or with blood pressure
measurements 3, 5, and 7, respectively); the comparisons which
were favorable to the device were utilized. The same procedure
was followed with diastolic blood pressure and heart rate
measurements.
Differences were separately classified for diastolic blood
pressure and systolic blood pressure, depending on whether the
difference was within 5, 10, or 15 mmHg [9] as well as for heart
rate depending on whether the difference was within 3, 5, or 8
bpm.
Results were analyzed and detailed according to ESH-IP2
requirements in order to determine if the device passed the
validation protocol. Accuracy was determined by the number
differences in these ranges for both individual measurements
(part 1) and individuals (part 2). To pass, a device must meet
the minimum pass requirements.
Furthermore, Bland-Altman plots were utilized to quantify
agreement between such systolic blood pressure, diastolic blood
pressure, and heart rate by constructing limits of agreement (a
graphical method in which the differences between both devices
are used to compare two measurements of the same variable).
All analyses were carried out with SPSS statistical software
(version 19.0; IBM Corp). In all analyses, the threshold for




All the sociodemographic variables showed a normal distribution
(P>.05, Table 1). A sample of 37 participants diagnosed with
noninsulin-dependent type 2 diabetes were recruited; 4 were
excluded due to device failure (n=2), arrhythmias (n=1), and
cuff size unavailability (n=1), therefore, there were 33
participants (17 men and 16 women) who met the ESH-IP2
inclusion criteria. Table 1 shows participant demographic
characteristics.
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Table 1. Demographic characteristics and descriptive data of the participants.

















Blood Pressure Outcome Measurements
Parts 1 and 2 of the validation according to the ESH-IP2 for the
QardioArm blood pressure are presented in Table 2; the number
of differences between the device and reference for systolic
blood pressure and diastolic blood pressure classified within 5,
10, or 15 mmHg are detailed.
Mean differences between the QardioArm and Omron M3 were
3.37 (SD 3.19) mmHg for diastolic blood pressure and 3.15 (SD
4.67) mmHg for systolic blood pressure.
A total of 87/99 differences (89%) for systolic blood pressure
and a total of 88/99 differences (89%) for diastolic blood
pressure showed an absolute difference within 5 mmHg
(ESH-IP2 criteria: at least 65 for diastolic blood pressure and
at least 73 for systolic blood pressure). Furthermore, a total of
95/99 comparisons (96%) for systolic blood pressure and a total
of 96/99 (97%) for diastolic blood pressure showed an absolute
difference within 10 mmHg (ESH-IP2 criteria: at least 81 for
diastolic blood pressure and at least 87 for systolic blood
pressure). A total of 98/99 differences (99%) for systolic blood
pressure and a total of 99/99 differences (100%) for diastolic
blood pressure exhibited an absolute difference within 15 mmHg
(ESH-IP2 criteria: at least 93 for diastolic blood pressure and
at least 96 for systolic blood pressure). Part 1 of the validation
was successfully completed since 2 or more of the 3 absolute
difference ranges (within 5, 10, or 15 mmHg) for systolic blood
pressure met the minimum requirements, and 3 out of 3 absolute
difference ranges for diastolic blood pressure met the minimum
requirements.
A total of 32/33 patients (97%) for systolic blood pressure and
a total of 29/33 patients (88%) for diastolic blood pressure
showed a minimum of 2 out of 3 differences within 5 mmHg
(ESH-IP2 criteria: at least 24 out of 33 patients for systolic
blood pressure and at least 24 out of 33 patients for diastolic
blood pressure). Nevertheless, 1/33 patients (3%) had 3
differences outside 5 mmHg for systolic blood pressure, though
0/33 patients (0%) had 3 differences outside 5 mmHg for
diastolic blood pressure (ESH-IP2 criteria: a maximum of 3
patients for diastolic blood pressure and systolic blood pressure
according to the ESH-IP2 criteria. Part 2 of the device validation
was successfully completed; therefore, part 3 of the QardioArm
device validation was passed, since parts 1 and 2 were both
passed for diastolic blood pressure and systolic blood pressure.
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Table 2. Number of measurement differences in each range.
Difference (mmHg), mean (SD)Achieved (N=99), nESH-IP2 requirement, nMeasurement type and range
For all 3 rangesFor 2 of 3 ranges
Part 1












Heart Rate Outcome Measurements
Parts 1 and 2 of the validation according to the ESH-IP2 for
heart rate are also shown in Table 2 and Table 3; the number
of differences between QardioArm and the standard device,
Omron M3, within 3, 5, and 8 bpm are detailed. The mean
difference between the tested device and standard was 1.65 (SD
2.91) bpm.
A total of 91/99 differences (92%) showed an absolute
difference within 3 bpm, a total of 96/99 comparisons (97%)
showed an absolute difference within 5 bpm, and a total of 99/99
differences (100%) showed an absolute difference within 8 bpm.
Thus, part 1 of the device validation was successfully completed
for the heart rate.
Table 3. Within-participant measurement differences.
0 of 3 measurements2 of 3 measurementsMeasurement type and range








A total of 31/33 participants (94%) had a minimum of 2 of 3
comparisons within 3 bpm difference for heart rate.
Nevertheless, a total of 1/33 participants (3%) had 3 differences
greater than 3 bpm; therefore, part 2 of the device validation
was successfully completed for heart rate, and consequently,
part 3 of the QardioArm device validation was passed.
Indeed, the QardioArm device met the validation criteria of the
ESH-IP2 for heart rate, systolic blood pressure, and diastolic
blood pressure for this sample of 33 individuals with
noninsulin-dependent type 2 diabetes.
The Bland-Altman plots show the differences between
QardioArm and Omron M3 measurements for systolic blood
pressure (Figure 1), diastolic blood pressure (Figure 2), and
heart rate (Figure 3).
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Figure 1. Bland-Altman plot showing differences between QardioArm and Omron M3 measurements for systolic blood pressure.
Figure 2. Bland-Altman plot showing differences between QardioArm and Omron M3 measurements for diastolic blood pressure.
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Figure 3. Bland-Altman plot showing differences between QardioArm and Omron M3 measurements for heart rate.
Discussion
As far as we know, this is the first study to validate an upper
arm oscillometric wireless device connected to an app to
measure heart rate and blood pressure in a population with
noninsulin-dependent type 2 diabetes. QardioArm was validated
in 2017 [36,37] in the general population. Furthermore,
QardioArm has also been validated in a population of obese
individuals in 2018 [38], and recently, in a population of
individuals with chronic kidney disease [39].
The results of this study have shown that QardioArm device
passed both parts of the validation [9] in patients diagnosed
with noninsulin-dependent type 2 diabetes as hypothesized.
This validation has been carried out following the ESH-IP2
guidelines, although a validated noninvasive oscillometric upper
arm device was used as a reference instead a mercury
sphygmomanometer [3-6]. Our findings, however, should not
be extrapolated to other populations with other diseases.
We have already seen the enormous advantages of home blood
pressure monitoring, especially in specific populations prone
to hypertension, such as persons with diabetes. Chronic diseases
such as diabetes are one of the most common pathologies and
have significant physical, psychological, social, and economic
impacts [3,8,16,17,19-25,28,29,32]. mHealth and apps that
assess blood pressure are progressively gaining a fundamental
role in the management of hypertension with the potential to
improve the quality of managed care by offering additional
advantages, especially when it comes to blood pressure
self-measurement. Advantages could include assisting in
lowering blood pressure [3,40,41]; enabling individuals to have
24-hour access to detailed and personalized blood pressure
information [40,42]; improving adherence to treatment [3,43];
providing information to facilitate diagnostic and therapeutic
decisions [40,41,43,44]; improving patient knowledge of blood
pressure, lifestyle, and risk factors that may accompany
hypertension [40,42,43]; more effectively preventing
cardiovascular complications [43]; or health cost savings by
avoiding unnecessary hypertensive treatment and reducing the
number of visits to the clinic [3,42].
Nevertheless, we found very few studies analyzing the validity
of automatic blood pressure monitors in a population with
noninsulin-dependent type 2 diabetes, [37,45-48], and
furthermore, most of these validations did not follow specific
protocols such as ESH-IP2 [9-11].
Only one study by Chahine et al [37] was found that followed
the same recommendations as those of the ESH-IP2 [9]. They
validated Omron M6 IT Comfort using a mercury
sphygmomanometer as the standard. If we compare our results
with their results [37], the number of differences for each
category (5, 10, and 15 mmHg) for the systolic blood pressure
and the diastolic blood pressure were similar in the two
validations, and parts 1 and 2 were passed in both. QardioArm
achieved better results in part 1 of the protocol, especially for
diastolic blood pressure with a number of higher differences in
the 3 categories. Within part 2, QardioArm and Omron M6
differed in 3 individuals for the first criterion (2 of 3
comparisons within 5 mmHg difference) for both systolic and
diastolic pressure, in favor of QardioArm. The results of the
second criterion (3 differences outside 5 mmHg) were almost
identical for both devices. On the other hand, the data obtained
for heart rate cannot be compared because Chahine and company
[37] did not assess this variable.
Another important fact is that measurements of people with
type 2 diabetes involve stiffer arteries; however, in our study
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